Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GDTC
#4971
CytoMed Therapeutics Limited Ordinary Shares
1.0
8
+5.88%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+5.88%
Mudança mensal
+35.00%
Mudança em 6 meses
-46.27%
Mudança anual
-59.85%
Fechamento anterior
1.0
2
Open
1.0
8
Bid
Ask
Low
1.0
8
High
1.0
8
Volume
1
Mercados
Ações
Cuidados de saúde
GDTC
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
11.54 M
—
Valuation ratios
Enterprise value
39.24 M
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
Notícias
Ações da CytoMed sobem após anúncio de parceria para ensaio clínico na Malásia
CytoMed stock jumps after announcing clinical trial partnership in Malaysia
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital
CytoMed Therapeutics garante investimento de US$ 500.000 para subsidiária
CytoMed Therapeutics secures $500,000 investment for subsidiary
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
CytoMed apresenta resultados pré-clínicos promissores para tratamento de leucemia
CytoMed reports promising preclinical results for leukemia treatment
CytoMed Therapeutics shareholders approve all proposals at annual meeting
CytoMed Therapeutics schedules annual shareholder meeting